Article
PI3K at the crossroads of tumor angiogenesis signaling pathways
26 Feb 2015
Abstract excerpt
Tumors need blood vessels for their growth, thus providing the rationale for antiangiogenic therapy in cancer treatment. However, intrinsic and acquired resistance and low response rates have turned out to be major limitations of antiangiogenic therapy. This emphasizes the need to further understand how the vasculature in cancer can be targeted. Although endothelial cells (ECs) rely on multiple growth factors and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
